S100B Serum Level as a Mortality Predictor for Traumatic Brain Injury: A Meta-Analysis

Authors

  • Nyoman Golden Department of Neurosurgery, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali
  • Tjokorda Gde Bagus Mahadewa Department of Neurosurgery, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali
  • Citra Aryanti Department of Neurosurgery, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali
  • I Putu Eka Widyadharma Department of Neurology, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali http://orcid.org/0000-0002-4554-0348

DOI:

https://doi.org/10.3889/oamjms.2018.432

Keywords:

traumatic brain injury, S100B serum level, mortality

Abstract

 

BACKGROUND: The pathogenesis of inflammatory neuronal cell damage will continue after traumatic brain injury in which contributed to subsequent mortality. Serum S100B levels were shown to be an early predictor of mortality due to traumatic brain injury.

AIM: This Meta-Analysis will analyse the mean and diagnostic strength of serum S100B levels between survived and died subjects with head injuries based on the various follow-up times of nine studies.

METHODS: We conducted a meta-anelysis in accordance with PRISMA guidelines and adhering to Cochrane Handbook for Systematic Review of Interventions. Literature search was conducted on March 16, 2018 from Medline and Scopus in the past 10 years, using various keywords related to S100, brain injury, and outcome. Duplicate journals were sorted out via EndNote. Included articles were as follows: original data from the group, clinical trials, case series, patients undergoing serum S100B levels with both short- and long-term follow-up mortality. Data were collected for mortality, serum S100B levels, and its diagnostic strength. All data were analyzed using Review Manager 5.3 (Cochrane, Denmark).

RESULTS: The results of the meta-analysis showed a significant difference in S100B levels between survived and died subjects with head injuries on overall follow-up timeline (0.91, 95.9% CI 0.7-1.12, I2 = 98%, p < 0.001), during treatment (1.43, 95% CI 0.97 to 1.89, I2 = 98%, p < 0.001), or 6 months (0.19; 95%CI 0.1-0.29, I2 = 76%, p < 0.001) with an average threshold value that varies according to the study method used. The mean diagnostic strength was also promising to predict early mortality (sensitivity of 77.18% and 92.33%, specificity of 78.35% and 50.6%, respectively).

CONCLUSION: S100B serum levels in the future will be potential biomarkers, and it is expected that there will be standardised guidelines for their application.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Marr AL, Coronado VG. Central nervous system injury surveillance data submission standards—2002. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 2004.

Medical records derived from Sanglah Hospital. Sanglah Hospital, 2011.

Pentland B, Hutton LS, Jones PA. Late mortality after traumatic brain injury. J Neurol Neurosurg Psychiatry. 2005; 76:395-400. https://doi.org/10.1136/jnnp.2004.037861 PMid:15716535 PMCid:PMC1739527

Bloomfield SM, McKinney J, Smith L, et al. Reliability of S100Î’ in predicting the severity of central nervous system injury. Neurocrit Care. 2007; 6:121-38. https://doi.org/10.1007/s12028-007-0008-x PMid:17522796

Lafrenaye AD, Krahe TE, Povlishock JT. Moderately elevated intracranial pressure after diffuse traumatic brain injury is associated with exacerbated neuronal pathology and behavioural morbidity in the rat. J Cereb Blood Flow Metab. 2014; 34(10):1628-36. https://doi.org/10.1038/jcbfm.2014.122 PMid:25027309 PMCid:PMC4269720

Van Beek JG, Mushkudiani NA, Steyerberg EW, Butcher I, McHugh GS, Lu J, Marmarou A, Murray GD, Maas AI. Prognostic value of admission laboratory parameters in traumatic brain injury: results from the IMPACT study. Journal of Neurotrauma. 2007; 24(2):315-28. https://doi.org/10.1089/neu.2006.0034 PMid:17375996

Adrian H, Marten K, Salla N, Lasse V. Biomarkers of traumatic brain injury: temporal changes in body fluids. eNeuro. 2016; 3(6):294-9. https://doi.org/10.1523/ENEURO.0294-16.2016 PMid:28032118 PMCid:PMC5175263

Mercier E, Boutin A, Lauzier F, Fergusson DA, Simard JF, Zarychanski R, et al. Predictive value of S-100beta protein for prognosis in patients with moderate and severe traumatic brain injury: systematic review and meta-analysis. BMJ. 2013; 346:1757-9. https://doi.org/10.1136/bmj.f1757 PMid:23558282

Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001; 33:637-68. https://doi.org/10.1016/S1357-2725(01)00046-2

Pfortmueller CA, Drexel C, Krahenmann-Muller S, Leichtle AB, Fiedler GM, Lindner G, et al. S-100 B Concentrations Are a Predictor of Decreased Survival in Patients with Major Trauma, Independently of Traumatic brain injury. PloS One. 2016; 11(3):1-5. https://doi.org/10.1371/journal.pone.0152822 PMid:27031106 PMCid:PMC4816449

Murillo-Cabezas F, Mu-oz-Sánchez MA, Rincón-Ferrari MD, et al. The prognostic alue of the temporal course of S100B eta protein in the post-acute severe brain injury: a prospective and observational study. Brain Inj. 2010; 24:609-19. https://doi.org/10.3109/02699051003652823 PMid:20235763

Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24 h) time-point. Resuscitation. 2009; 80:341-5. https://doi.org/10.1016/j.resuscitation.2008.11.021 PMid:19150161

Shakeri M, Mahdkhah A, Panahi F. S100B Protein as a Post-traumatic Biomarker for Prediction of Brain Death in Association With Patient Outcomes. Arch Trauma Res. 2013; 2:76-80. https://doi.org/10.5812/atr.8549 PMid:24396798 PMCid:PMC3876553

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 2009; 339:b2700.12.

Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0. 0. The Cochrane Collaboration. 2008. Available from www. cochrane-handbook. org (accessed 28 January 2010). 2008.

Rodríguez-Rodríguez A, Egea-Guerrero JJ, Gordillo-Escobar E, Enamorado-Enamorado J, Hernández-García C, Ruiz de Azúa-López Z, Vilches-Arenas Ã, Guerrero JM, Murillo-Cabezas F. S100B and Neuron-Specific Enolase as mortality predictors in patients with severe traumatic brain injury. Neurol Res. 2016; 38(2):130-7. https://doi.org/10.1080/01616412.2016.1144410 PMid:27078699

Rodríguez-Rodríguez A, Egea-Guerrero JJ, León-Justel A, Gordillo-Escobar E, Revuelto-Rey J, Vilches-Arenas A, Carrillo-Vico A, Domínguez-Roldán JM, Murillo-Cabezas F, Guerrero JM. Role of S100B protein in urine and serum as an early predictor of mortality after severe traumatic brain injury in adults. Clin Chim Acta. 2012; 414:228-33. https://doi.org/10.1016/j.cca.2012.09.025 PMid:23031665

Duda I, Krzych L, Jędrzejowska-Szypułka H, Lewin-Kowalik JL. Serum levels of the S100B protein and neuron-specific enolase are associated with mortality in critically ill patients. Biochimica Polonica. 2017; 64:16-9. https://doi.org/10.18388/abp.2017_1619

Olivecrona M, Rodling-Wahlström M, Naredi S, Koskinen LO. S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry. 2009; 80(11):1241-7. https://doi.org/10.1136/jnnp.2008.158196 PMid:19602473

Ballesteros MA, Rubio-Lopez MI, San Martín M, Padilla A, López-Hoyos M, Llorca J, Mi-ambres E. Serum levels of S100B from jugular bulb as a biomarker of poor prognosis in patients with severe acute brain injury. J Neurol Sci. 2018; 385:109-14. https://doi.org/10.1016/j.jns.2017.12.017 PMid:29406887

Gradisek P, Osredkar J, Korsic M, Kremzar B. Multiple indicators model of long-term mortality in traumatic brain injury. Brain Inj. 2012; 26(12):1472-81. https://doi.org/10.3109/02699052.2012.694567 PMid:22721420

Gerber LM, Chiu YL, Carney N, Hartl R, Ghajar J. Marked reduction in mortality in patients with severe traumatic brain injury. J Neurosurg. 2013; 119:1583-90. https://doi.org/10.3171/2013.8.JNS13276 PMid:24098983

Korfias S, Stranjalis G, Boviatsis E, et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. Intensive Care Med. 2007; 33:255-60. https://doi.org/10.1007/s00134-006-0463-4 PMid:17143637

Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V. Serum S-100B protein in severe traumatic brain injury. Neurosurgery. 1999; 45(3):477-83. https://doi.org/10.1097/00006123-199909000-00012 PMid:10493369

Goyal A, Failla MD, Niyonkuru C, Amin K, Fabio A, Berger RP, Wagner AK. S100b as a Prognostic Biomarker in Outcome Prediction for Patients with Severe Traumatic Brain Injury. J Neurotrauma. 2013; 30(11):946-57. https://doi.org/10.1089/neu.2012.2579 PMid:23190274 PMCid:PMC3684103

Anderson RE, Hansson LO, Liska J, Settergren G, Vaage J. The effect of cardiotomy suction on the brain injury marker S100B after cardiopulmonary by-pass. Ann Thorac Surg. 2000; 69:847– 50. https://doi.org/10.1016/S0003-4975(99)01526-X

Nishiyama H, Knopfel T, Endo S, Itohara S. Glial protein S100B modulates long-term neuronal synaptic plasticity. Proc Natl Acad Sci USA. 2002; 99:4037-42. https://doi.org/10.1073/pnas.052020999 PMid:11891290 PMCid:PMC122644

Herrmann M, Jost S, Kutz S, Ebert AD, Kratz T, Wunderlich MT, Synowitz H. Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. J Neurotrauma. 2000; 17:113-22. https://doi.org/10.1089/neu.2000.17.113 PMid:10709869

Ingebrigtsen T, Romner B, Kongstad P, Langbakk B. Increased serum concentrations of protein S-100 after minor traumatic brain injury: a biochemical serum marker with prognostic value? J Neurol Neurosurg Psychiatry. 1995; 59:103-4. https://doi.org/10.1136/jnnp.59.1.103-a PMid:7608699 PMCid:PMC1073618

de Kruijk JR, Leffers JR, Menheere PP, Meerhoff S, Twijnstra A. S100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with healthy controls. Acta Neurol Scand. 2001; 103:175-9. https://doi.org/10.1034/j.1600-0404.2001.103003175.x PMid:11240565

Kellermann I, Kleindienst A, Hore N, Buchfelder M, Brandner S. Early CSF and Serum S100B Concentrations for Outcome Prediction in Traumatic Brain Injury and Subarachnoid Hemorrhage. Clin Neurol Neurosurg. 2016; 145:79-83. https://doi.org/10.1016/j.clineuro.2016.04.005 PMid:27101088

Unden J, Bellner J, Astrand R, Romner B. Serum S100B levels in patients with epidural haematomas. Br J Neurosurg. 2005; 19: 43–45. https://doi.org/10.1080/02688690500089381 PMid:16147582

Schültke E, Sadanand V, Kelly ME, Griebel RW, Juurlink BHJ. Can admission S-100B predict the extent of brain damage in head trauma patients? Can J Neurol Sci. 2009; 36:612-6. https://doi.org/10.1017/S031716710000812X PMid:19831131

Woertgen C, Rothoerl RD, Brawanski A. Early S-100B serum level correlates to quality of life in patients after severe traumatic brain injury. Brain Inj. 2002; 16:807-16. https://doi.org/10.1080/02699050210128933 PMid:12217206

Muller K, Townend W, Biasca N, Unden J, Waterloo K, Romner B, Ingebrigtsen T. S100B serum level predicts computed tomography findings after minor traumatic brain injury. J Trauma. 2007; 62:1452-56. https://doi.org/10.1097/TA.0b013e318047bfaa PMid:17563665

Murray GD, Butcher I, McHugh GS, Lu J, Mushkudiani NA, Maas AI, Marmarou A, Steyerberg EW. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma. 2007; 24:329-37. https://doi.org/10.1089/neu.2006.0035 PMid:17375997

Thelin EP, Jeppsson E, Frostell A, Svensson M, Mondello S, Bellander BM, Nelson DW. Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity. Crit Care. 2016; 20:285. https://doi.org/10.1186/s13054-016-1450-y PMid:27604350 PMCid:PMC5015335

Pelinka LE, Toegel E, Mauritz W, Redl H. Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock. 2003; 19:195–200. https://doi.org/10.1097/00024382-200303000-00001 PMid:12630517

Wolf H, Frantal S, Pajenda G, Leitgeb J, Sarahrudi K, Hajdu S. Analysis of S100 calcium binding protein B serum levels in different types of traumatic intracranial lesions. J Neurotrauma. 2015; 32:23–27. https://doi.org/10.1089/neu.2013.3202 PMid:25068442

Published

2018-11-15

How to Cite

1.
Golden N, Mahadewa TGB, Aryanti C, Widyadharma IPE. S100B Serum Level as a Mortality Predictor for Traumatic Brain Injury: A Meta-Analysis. Open Access Maced J Med Sci [Internet]. 2018 Nov. 15 [cited 2022 May 19];6(11):2239-44. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2018.432

Issue

Section

F - Review Articles

Most read articles by the same author(s)

1 2 3 4 > >>